BeOne Medicines AG/$ONC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BeOne Medicines AG
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
- Ticker
- $ONC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 12,000
- Headquarters
- Basel, Switzerland
- Website
- beonemedicines.com
ONC Metrics
BasicAdvanced
$40B
63.42
$5.59
0.52
-
Price and volume
Market cap
$40B
Beta
0.52
52-week high
$385.22
52-week low
$253.95
Average daily volume
375K
Financial strength
Current ratio
3.405
Quick ratio
2.911
Long term debt to equity
0.338
Total debt to equity
0.396
Interest coverage (TTM)
7.97%
Profitability
EBITDA (TTM)
1,071.609
Gross margin (TTM)
88.89%
Net profit margin (TTM)
10.70%
Operating margin (TTM)
15.06%
Effective tax rate (TTM)
24.46%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
7.46%
Return on equity (TTM)
14.66%
Valuation
Price to earnings (TTM)
63.419
Price to revenue (TTM)
6.413
Price to book
7.74
Price to tangible book (TTM)
7.84
Price to free cash flow (TTM)
30.027
Free cash flow yield (TTM)
3.33%
Free cash flow per share (TTM)
11.805
Growth
Revenue change (TTM)
34.35%
Earnings per share change (TTM)
-436.23%
3-year revenue growth (CAGR)
50.14%
10-year revenue growth (CAGR)
96.54%
3-year earnings per share growth (CAGR)
-30.51%
10-year earnings per share growth (CAGR)
1.54%
What the Analysts think about ONC
Analyst ratings (Buy, Hold, Sell) for BeOne Medicines AG stock.
Analyst projections of the future price of BeOne Medicines AG stock.
Bulls say / Bears say
BRUKINSA still has strong commercial momentum: global sales rose 31% in the second quarter, and the company reported its highest sustained level of new patient starts since launch. Continued uptake across its approved uses could support further growth. (Morningstar, BeOne Medicines)
BeOne raised its 2026 revenue outlook to $6.6–$6.8 billion and its GAAP operating income outlook to $1.0–$1.1 billion after a strong first half. That points to sales growth translating into improving profitability. (Nasdaq)
TEVIMBRA offers a growing contribution beyond BRUKINSA: second-quarter global sales rose 18% to $229 million. The FDA’s approval of a first-line HER2-positive gastric cancer combination gives the drug a further route to expand in the US. (Morningstar, MarketChameleon)
The business remains heavily dependent on BRUKINSA, which generated about $1.2 billion of BeOne’s $1.7 billion in second-quarter product revenue. A competing acalabrutinib–venetoclax regimen is entering the market, and BeOne said it is too early to judge its effect. (Morningstar, Markets Daily)
The pipeline has meaningful development risk: BeOne discontinued four early-stage cancer programmes and stopped another cancer study, while also halting a Phase 2 arthritis trial. Such culls show that a broad research portfolio does not guarantee future products or sales. (Fierce Biotech)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
ONC Financial Performance
Revenues and expenses
ONC Earnings Performance
Company profitability
Upcoming events
No upcoming events
ONC News
AllArticlesVideos
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Investors Business Daily2 weeks ago
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
Business Wire1 month ago
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
Business Wire1 month ago
Funds containing ONC
AllGBPEURUSD
Fund name | Fund size | $ONC weighting |
|---|---|---|
iShares China Large Cap£FXC | £624M | 1.94% |
iShares Dow Jones China Offshore 50€EXXU | €42M | 1.80% |
iShares MSCI China€ICGA | €2.3B | 0.88% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.85% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.85% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.